Selective growth hormone secretagogue (GHS) that stimulates pulsatile GH release with minimal effects on cortisol and prolactin.
Last Updated: May 2026
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) and one of the most selective ghrelin receptor agonists studied for growth hormone release. It produces pulsatile GH secretion with minimal effects on cortisol, prolactin, or aldosterone — making it the cleanest GHRP profile in the class. Ipamorelin is not approved for any medical indication and is sold as a research-use-only compound by third-party laboratories.
Ipamorelin is a pentapeptide ghrelin receptor agonist (GHS-R1a) that stimulates pituitary growth hormone release with high selectivity, avoiding the cortisol and prolactin elevations seen with less selective GHRPs like GHRP-6 or hexarelin. It does not bind the ghrelin receptor in the hypothalamic nuclei responsible for appetite stimulation to the same degree as GHRP-6, so it does not produce significant hunger effects. Half-life is approximately 2 hours, supporting multiple-daily-dose research protocols. Evidence level: Human Phase 2 (postoperative ileus, abandoned); preclinical mechanism extensive.
Ipamorelin was developed by Novo Nordisk and reached Phase 2 trials for postoperative ileus, where it failed to meet primary efficacy endpoints and was discontinued for that indication. Subsequent research interest has focused on its clean GH-release profile for research protocols. In human pharmacokinetic studies, ipamorelin reliably produces dose-dependent GH spikes and modest IGF-1 elevation with daily-dose protocols. No Phase 3 efficacy trial for any indication has been published. Evidence level: Phase 2 human (postoperative ileus, failed primary endpoint); preclinical and Phase 1 PK extensive.
Ipamorelin is the most selective ghrelin-receptor GHS in the GHRP class — same mechanism family as GHRP-2, GHRP-6, and hexarelin, but with substantially cleaner side effect profile. The trade-off is GH-release magnitude: hexarelin produces the strongest single-dose GH spike, ipamorelin produces the cleanest spike.
| GHS peptide | GH release strength | Selectivity | Cortisol/prolactin effects | Appetite effects |
|---|---|---|---|---|
| Ipamorelin | Moderate | Highest | Minimal | Minimal |
| GHRP-2 | Strong | Moderate | Mild cortisol/prolactin rise | Mild |
| GHRP-6 | Strong | Lower | Mild cortisol/prolactin rise | Significant (appetite increase) |
| Hexarelin | Strongest | Lowest | Significant cortisol/prolactin rise | Mild |
Ipamorelin's side effect profile is among the cleanest in the GHRP class — typically mild injection-site reactions and occasional transient flushing. Unlike other GHRPs, it does not produce significant cortisol or prolactin elevation, and appetite effects are minimal. Long-term safety in humans at sustained research-use dosing is unknown given the absence of completed long-duration trials. Evidence level: Phase 2 human safety data (postoperative ileus); long-term unestablished.
Ipamorelin is not approved for any medical indication anywhere in the world as of May 2026. The Novo Nordisk Phase 2 program for postoperative ileus was discontinued; no other clinical program is currently advancing. Ipamorelin is sold strictly as a research-use-only compound by third-party laboratories. Regulatory context in are peptides legal regulatory status by country.
Ipamorelin is one of the most widely-sold research-grade GH peptides, and its small molecular size makes synthesis straightforward — but quality variance across vendors is still substantial. Some vendors mislabel longer-chain GHRP analogs as ipamorelin. Independent HPLC purity testing and mass spectrometry identity confirmation (expected MW 711.8 Da) are the meaningful purity signals. Guidance in how-to-test-peptides hub.
Peptigrity purchases ipamorelin vials anonymously at standard customer pricing, sends them to ISO-accredited third-party labs for HPLC and mass spectrometry analysis, and publishes the unedited certificate of analysis. The lab test table above this section shows the cross-shop dataset. Tests come from labs including Janoshik Analytical, Freedom Diagnostics, and Chromate. Methodology in how we calculate trust scores.
The only reliable purity signal is an independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay. For ipamorelin specifically, mass spectrometry identity confirmation is particularly relevant — mislabeling with related pentapeptide GHRP analogs occurs in the market. COA interpretation in red flags in peptide certificates of analysis.
Ipamorelin is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption. Country breakdown in peptide legal status guide.
No active clinical development program for ipamorelin exists as of May 2026. The Novo Nordisk Phase 2 program was discontinued. FDA approval is unlikely without a renewed development effort by a pharmaceutical sponsor.
Mechanistically, ghrelin-receptor GHS peptides like ipamorelin and GHRH analogs like CJC-1295 without DAC act on complementary pathways — GHS amplifies GHRH-mediated pituitary signaling — and the combination has been a long-standing research-protocol convention. Peptigrity does not recommend specific stacking protocols; this is medical practice that requires physician oversight.
Pharmacologically by side effect profile — GHRP-2 and GHRP-6 produce mild cortisol/prolactin elevation and (for GHRP-6) substantial appetite stimulation; ipamorelin produces neither. Chemically by mass — ipamorelin's molecular weight (711.8 Da) differs from GHRP-2 (817.0) and GHRP-6 (873.0). Mass spectrometry distinguishes them definitively.
No. Ipamorelin is not approved for human consumption and Peptigrity is an independent review platform, not a medical authority. Research-use dosing in community protocols varies widely. Anyone considering use should consult a licensed physician.
This section is for educational and informational purposes only and does not constitute medical advice. Ipamorelin is not approved by the FDA or any other regulator for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
Real protocols and questions from members — independent of vendors, never sponsored.
Sign in to ask a question.
Every submitted test helps the community verify purity across brands. Free, fast, independent.